s6y Altamira Therapeutics Ltd. 20-F

Altamira Therapeutics Ltd. 20-F, filed May 16, 2023: IDEA: XBRL DOCUMENT

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument - CHF (SFr)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Derivative financial instrument [Member]    
Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]    
Balance SFr 1,233 SFr 316,757
Financing Cash Flows [1]
Fair value revaluation (1,233) 410,918
Other changes [2] (726,442)
Balance 1,233
Loans [Member]    
Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]    
Balance 523,920
Financing Cash Flows [1] 6,038,627 (50,000)
Fair value revaluation
Other changes [2] (168,830) (473,920)
Balance 5,869,797
Lease liabilities [Member]    
Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]    
Balance 575,736
Financing Cash Flows (130,200) (21,700) [1]
Fair value revaluation
Other changes 15,949 597,436 [2]
Balance 461,485 575,736
Total [Member]    
Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]    
Balance 576,969 840,677
Financing Cash Flows [1] 5,908,427 (71,700)
Fair value revaluation (1,233) 410,918
Other changes [2] (152,881) (602,926)
Balance SFr 6,331,282 SFr 576,969
[1] The financing cash flows are from loan borrowings or loan and lease repayments.
[2] Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability.